Oppenheimer Likes This Cancer Stock Before Earnings

Allogene Therapeutics will report earnings on May 7

May 3, 2019 at 2:08 PM
facebook twitter linkedin

Ahead of earnings next Tuesday, May 7, Oppenheimer initiated coverage of Allogene Therapeutics Inc (NASDAQ:ALLO) with an "outperform" rating. In addition, the brokerage firm set a lofty price target of $45 -- a 51% premium to Thursday's close. The brokerage firm waxed optimistic on Allogene's off-the-shelf CAR-Ts prospects and its allogeneic product pipeline.

ALLO went public back in October, pricing its initial public offering (IPO) at $18 per share. The security notched an all-time high of $35.55 -- almost twice its IPO price -- in early November, but has subsequently run into resistance in the $33-$34 area. A rally to $45 would represent 2.5 times ALLO's IPO price, and uncharted territory. At last check, the shares were up 1.4% to trade at $30.13.

 ALLO stock chart may 3

While most analysts already lean bullishly toward Allogene shares -- five of six brokerage firms offer up "buy" or better endorsements -- a strong earnings showing next week could trigger a short squeeze. Short interest surged 17.7% during the past two reporting periods, and now accounts for 11.2% of the equity's total available float. At ALLO's average pace of trading, it would take more than 25 sessions to repurchase these pessimistic positions.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Best stocks for October and worst stocks for October


Special Offers from Schaeffer's Trading Partners